CRISPR-Cas9 BCL11A enhancer disruption for SCD HBB c.20A>T: exa-cel clinical outcomes

CRISPR-Cas9-mediated disruption of the BCL11A erythroid-specific enhancer in autologous CD34+ HSPCs reactivates fetal hemoglobin (HbF) and has achieved near-complete elimination of vaso-occlusive crises in sickle cell disease patients homozygous for HBB c.20A>T (p.Glu7Val). Exagamglogene autotemcel (exa-cel/Casgevy) received FDA approval in December 2023 and MHRA approval in November 2023, becoming the first CRISPR-based therapy approved for any human disease.

The pivotal CLIMB-121 trial (NCT03745287, completed) enrolled patients with severe SCD (≥2 VOC/year). Published results in the New England Journal of Medicine (PMID:38661449) demonstrated that 29 of 30 evaluable patients were free of vaso-occlusive crises at 12+ months, with sustained HbF >20%% (mean ~40%%). The approach edits the BCL11A erythroid enhancer rather than correcting the HBB variant directly, bypassing the pathogenic p.Glu7Val mutation by reactivating gamma-globin. ClinVar classifies this variant (VCV000446735) as pathogenic with expert panel review. A pediatric trial (NCT05329649) is active but not yet recruiting. Longer-term follow-up study NCT04208529 is ongoing.

Therapy requires myeloablative busulfan conditioning, which carries significant toxicity including prolonged cytopenias, mucositis, hepatic sinusoidal obstruction syndrome, and gonadotoxicity/infertility risk. Off-target editing has been assessed by GUIDE-seq and Digenome-seq, but genome-wide off-target effects in long-term engrafted cells need continued monitoring. Durability beyond 3-4 years is still being characterized. The cost (~$2.2M per treatment) and manufacturing complexity (autologous ex vivo editing requiring apheresis, GMP manufacturing, and cryopreservation) severely limit accessibility in sub-Saharan Africa where >75%% of the global SCD burden exists. Patients with pre-existing end-organ damage may have limited benefit from HbF reactivation alone.